Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.

Schramm C, Edwards MA, Krenz M.

J Biol Chem. 2013 Jun 21;288(25):18335-44. doi: 10.1074/jbc.M113.483800.

2.

The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.

Schramm C, Fine DM, Edwards MA, Reeb AN, Krenz M.

Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H231-43. doi: 10.1152/ajpheart.00665.2011.

3.

LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.

Ishida H, Kogaki S, Narita J, Ichimori H, Nawa N, Okada Y, Takahashi K, Ozono K.

Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1531-9. doi: 10.1152/ajpheart.00216.2011.

4.

Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.

Marin TM, Clemente CF, Santos AM, Picardi PK, Pascoal VD, Lopes-Cendes I, Saad MJ, Franchini KG.

Circ Res. 2008 Oct 10;103(8):813-24. doi: 10.1161/CIRCRESAHA.108.179754.

5.

Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling.

Edouard T, Combier JP, Nédélec A, Bel-Vialar S, Métrich M, Conte-Auriol F, Lyonnet S, Parfait B, Tauber M, Salles JP, Lezoualc'h F, Yart A, Raynal P.

Mol Cell Biol. 2010 May;30(10):2498-507. doi: 10.1128/MCB.00646-09.

6.

Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.

Bonetti M, Paardekooper Overman J, Tessadori F, Noël E, Bakkers J, den Hertog J.

Development. 2014 May;141(9):1961-70. doi: 10.1242/dev.106310.

7.

Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.

Kontaridis MI, Yang W, Bence KK, Cullen D, Wang B, Bodyak N, Ke Q, Hinek A, Kang PM, Liao R, Neel BG.

Circulation. 2008 Mar 18;117(11):1423-35. doi: 10.1161/CIRCULATIONAHA.107.728865. Erratum in: Circulation.2008 Apr 15;117(15) e314.

8.

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, Bronson R, Franchini KG, Neel BG, Kontaridis MI.

J Clin Invest. 2011 Mar;121(3):1026-43. doi: 10.1172/JCI44972.

9.

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Zhang RY, Walls CD, Chen L, Zhang S, Wu L, Liu S, Zhang ZY.

Biochemistry. 2014 Jul 1;53(25):4136-51. doi: 10.1021/bi5002695.

10.

Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.

Clemente CF, Xavier-Neto J, Dalla Costa AP, Consonni SR, Antunes JE, Rocco SA, Pereira MB, Judice CC, Strauss B, Joazeiro PP, Matos-Souza JR, Franchini KG.

J Mol Cell Cardiol. 2012 Feb;52(2):493-501. doi: 10.1016/j.yjmcc.2011.10.015.

PMID:
22056317
11.

Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, Tzeng CM.

Curr Cancer Drug Targets. 2014;14(6):567-88. Review.

PMID:
25039348
12.

Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.

Noda S, Takahashi A, Hayashi T, Tanuma S, Hatakeyama M.

Biochem Biophys Res Commun. 2016 Jan 22;469(4):1133-9. doi: 10.1016/j.bbrc.2015.12.117.

PMID:
26742426
13.

Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.

Jopling C, van Geemen D, den Hertog J.

PLoS Genet. 2007 Dec;3(12):e225.

14.

Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity.

Burmeister BT, Wang L, Gold MG, Skidgel RA, O'Bryan JP, Carnegie GK.

J Biol Chem. 2015 May 8;290(19):12058-67. doi: 10.1074/jbc.M115.642983.

15.

SHP2 mediates gp130-dependent cardiomyocyte hypertrophy via negative regulation of skeletal alpha-actin gene.

Nakaoka Y, Shioyama W, Kunimoto S, Arita Y, Higuchi K, Yamamoto K, Fujio Y, Nishida K, Kuroda T, Hirota H, Yamauchi-Takihara K, Hirano T, Komuro I, Mochizuki N.

J Mol Cell Cardiol. 2010 Aug;49(2):157-64. doi: 10.1016/j.yjmcc.2010.03.001.

PMID:
20226789
16.

Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R, Wu L, Wang L, Liu S, Zhang ZY.

J Biol Chem. 2013 Apr 12;288(15):10472-82. doi: 10.1074/jbc.M113.450023.

17.

Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes.

Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H.

Circ Res. 2003 Aug 8;93(3):221-9.

18.

LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.

Tajan M, Batut A, Cadoudal T, Deleruyelle S, Le Gonidec S, Saint Laurent C, Vomscheid M, Wanecq E, Tréguer K, De Rocca Serra-Nédélec A, Vinel C, Marques MA, Pozzo J, Kunduzova O, Salles JP, Tauber M, Raynal P, Cavé H, Edouard T, Valet P, Yart A.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4494-503. doi: 10.1073/pnas.1406107111.

19.

Rapamycin prevents thyroid hormone-induced cardiac hypertrophy.

Kuzman JA, O'Connell TD, Gerdes AM.

Endocrinology. 2007 Jul;148(7):3477-84.

PMID:
17395699
20.

Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.

Hellmuth K, Grosskopf S, Lum CT, Würtele M, Röder N, von Kries JP, Rosario M, Rademann J, Birchmeier W.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7275-80. doi: 10.1073/pnas.0710468105.

Supplemental Content

Support Center